2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
2
Sponsor Class
INDUSTRY
31
OTHER
27
NETWORK
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
1
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Radiotherapy
302
Cisplatin
266
Cyclophosphamide
230
Doxorubicin
177
Paclitaxel
170
Vincristine
162
Carboplatin
152
Filgrastim
140
Etoposide
139
Gemcitabine
118
Docetaxel
114
Fluorouracil
113
Methotrexate
106
Dexamethasone
106
Cytarabine
106
Prednisone
92
Leucovorin
90
Gene Expression Profiling
82
Granulocyte Colony-Stimulating Factor
75
Specimen Handling
70
Magnetic Resonance Spectroscopy
63
Irinotecan
59
Capecitabine
59
Radiation
54
Polymerase Chain Reaction
51
Ifosfamide
51
Rituximab
49
Immunohistochemistry
49
Daunorubicin
49
Oxaliplatin
48
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
NETWORK
×
belantamab mafodotin
×
Clear all
NCT04617925
2025-09-05
EMN27
European Myeloma Network B.V.
Phase 2
Completed
35 enrolled
NCT03732703
2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2
Completed
103 enrolled